Henry Li

Hanx Biopharmaceuticals, Inc.

BIOGRAPHY

Henry Li is the Chief Executive Officer and the Chief Scientific Officer at Hanx Biopharmaceuticals, a biopharmaceutical company focused on developing antibody therapies for cancer and autoimmune diseases. His responsibilities encompass corporate strategy, therapeutic pipeline development, and oversight of day-to-day operations.

Henry previously served as the Chief Scientific Officer at Crown Bioscience, building preclinical and translational platforms for oncology, including large-scale patient-derived disease model collections. His published works include three edited books on drug development technologies and nearly 100 peer-reviewed publications in oncology and virology.